Key molecular scaffolds in the development of clinically viable α-amylase inhibitors DOI
Rahul Pratap Singh, Jayant Sindhu,

Devender Singh

и другие.

Future Medicinal Chemistry, Год журнала: 2025, Номер 17(3), С. 347 - 362

Опубликована: Янв. 21, 2025

The escalating cases of type II diabetes combined with adverse side effects current antidiabetic drugs spurred the advancement innovative approaches for management postprandial glucose levels. α-Amylase is an endoamylase responsible breakdown internal α-1,4-glycosidic linkages in dietary starch, producing oligosaccharides. Subsequently, α-glucosidase degraded these oligosaccharides to monosaccharides, which are absorbed into bloodstream and become available body. inhibitors α-amylase reduced digestibility carbohydrates accompanied by delayed absorption, leading decreased blood levels after meals thus, inhibition enzyme seems be a crucial strategy improving overall glycemic control diabetic patients. present review article emphasizes therapeutic promise recently discovered potential inhibitors, highlighting their vitro, silico vivo profiles. Ultimately, we addressed contemporary challenges routes ahead search safe reliable clinical use, summarizing most recent research field.

Язык: Английский

Key molecular scaffolds in the development of clinically viable α-amylase inhibitors DOI
Rahul Pratap Singh, Jayant Sindhu,

Devender Singh

и другие.

Future Medicinal Chemistry, Год журнала: 2025, Номер 17(3), С. 347 - 362

Опубликована: Янв. 21, 2025

The escalating cases of type II diabetes combined with adverse side effects current antidiabetic drugs spurred the advancement innovative approaches for management postprandial glucose levels. α-Amylase is an endoamylase responsible breakdown internal α-1,4-glycosidic linkages in dietary starch, producing oligosaccharides. Subsequently, α-glucosidase degraded these oligosaccharides to monosaccharides, which are absorbed into bloodstream and become available body. inhibitors α-amylase reduced digestibility carbohydrates accompanied by delayed absorption, leading decreased blood levels after meals thus, inhibition enzyme seems be a crucial strategy improving overall glycemic control diabetic patients. present review article emphasizes therapeutic promise recently discovered potential inhibitors, highlighting their vitro, silico vivo profiles. Ultimately, we addressed contemporary challenges routes ahead search safe reliable clinical use, summarizing most recent research field.

Язык: Английский

Процитировано

0